BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Engages PCAOB Auditor to Support Planned OTCQB Uplist 

Fifty 1 Labs (OTC: FITY), a Nevada-based holding company focused on AI-driven drug repurposing and functional medicine, announced it has signed a letter of engagement with a Public Company Accounting Oversight Board registered auditing firm to conduct audits of its 2024 and 2025 financial statements. The audits mark a key step in the company’s plan to uplist to the OTCQB Venture Market, which requires strict reporting and governance standards. CEO Paul Arora said the engagement underscores Fifty 1 Labs’ commitment to transparency and corporate governance, while laying the groundwork to strengthen investor confidence as it advances biotech and wellness initiatives.

To view the full press release, visit https://ibn.fm/iZbQS

About Fifty1 AI Labs

Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY), is redefining drug discovery by using AI to unlock new potential in proven medicines. By repurposing safe, off-patent compounds, we accelerate smarter therapies that improve lives, reduce costs, and create lasting value for patients, partners, and forward-thinking investors.

For more information, visit the company’s website at https://fifty1labs.com/

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN